As pancreatic islets are closely associated with the development of diabetes, islet organoids have received increasing attention. Ace Therapeutics is committed to providing high-quality pancreatic islet organoids, especially human pluripotent stem cell-derived islet organoids, which are promising models for the study of diabetes.
The pancreatic islets, also known as the islets of Langerhans, are microorgans within the pancreas that play a critical role in regulating blood glucose levels by secreting hormones such as insulin and glucagon. Islet organoids represent a cutting-edge technology that allows researchers to create three-dimensional structures resembling native pancreatic islets in vitro. Studies have shown that islet organoids can recapitulate key features of native islets, including the ability to respond to glucose stimulation by secreting insulin. This functional similarity to native islets makes organoids a valuable tool for investigating the pathophysiology of diabetes and testing potential therapeutic regimens.
Fig. 1. Strategies currently leveraged to establish 3D islet organoids. (Zhang X, et al., 2022)
The construction of our pancreatic islet organoid models relies on a combination of advanced cell culture techniques, biomaterial engineering, and three-dimensional technologies. By carefully orchestrating the interaction between seed cells and biomaterial matrices, we can cultivate organoids that closely mirror the structural and functional characteristics of human pancreatic islets.
Pancreatic endocrine cells, as seed cells, are essential for constructing the main body of pancreatic islet-like functional organoids. Our team has meticulously explored the potential of cells from different sources for organoid culture, including embryonic stem cells, induced pluripotent stem cells, and adult stem/progenitor cells derived from the pancreas, and other tissues. By employing sophisticated differentiation strategies, we can help our clients generate pancreatic endocrinal cells for islet organoid culture.
We use various biomaterials as 3D scaffolds for islet organoid construction. These biomaterials not only support the growth and survival of the cells but also mimic the extracellular matrix found in the native pancreatic microenvironment, ensuring the organoids maintain their physiological relevance. The materials we use include:
| Material Types | Natural matrix biomaterial | Synthetic matrix material |
| Classification |
|
|
| Advantages |
|
|
We provide a more realistic environment for pancreatic islet organoids and structural tissue similar to natural human islets through 3D cultivation technology. Our technologies for constructing islet organoid 3D structures include traditional self-aggregation methods, modified self-aggregation methods, hydrogel-based embedding, 3D bioprinting, decellularized organ scaffolds, etc.
Through gene editing technologies, such as CRISPR/Cas9, and refined iPSC technology, our researchers help clients manipulate islet organoid models to study diabetes, including:
Through our expertise in stem cell biology, tissue engineering, and diabetes research, Ace Therapeutics offers tailored solutions for studying the function and dysfunction of the pancreatic islet in vitro. Please contact us for more services to accelerate your diabetes research.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
